Piscataway, NJ, July 30, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Diatrizoate Meglumine and Diatrizoate Sodium Solution, USP to its product line.
Diatrizoate Meglumine and Diatrizoate Sodium Solution, USP is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous.
Diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.
Diatrizoate Meglumine and Diatrizoate Sodium Solution, USP are available in strengths of 66-10 % in 30 mL x 24 Single -Dose vials and 120 mL x 12 Single-Dose Vials.
To learn more about Diatrizoate Meglumine and Diatrizoate Sodium Solution, USP please visit https://www.camberpharma.com/dmds
